Pralsetinib Achieves Tissue-agnostic Benefits for Patients With RET Gene Fusions
August 13, 2022
August 13, 2022
HOUSTON, Texas, Aug. 13 (TNSjou) -- The University of Texas's MD Anderson Cancer Center issued the following news release on Aug. 12, 2022:
* * *
Phase I/II trial suggests targeted therapy may be effective option across cancer types
* * *
The highly selective RET inhibitor pralsetinib was well-tolerated and demonstrated robust, durable responses in patients with RET fusion-positive cancers regardless of tumor type, according to results fro . . .
* * *
Phase I/II trial suggests targeted therapy may be effective option across cancer types
* * *
The highly selective RET inhibitor pralsetinib was well-tolerated and demonstrated robust, durable responses in patients with RET fusion-positive cancers regardless of tumor type, according to results fro . . .